

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.
Follow the sample format on for each person. (See attached sample). **DO NOT EXCEED FOUR PAGES.**

NAME		POSITION TITLE	
Deborah Lynn Ackerman		Adj. Assoc. Professor and Assoc. Research Epidemiologist	
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Wisconsin, Madison	B.A.	1972	Philosophy
University of Wisconsin, School of Pharmacy, Madison	M.S.	1978	Pharmacology
University of California, School of Public Health	Ph.D.	1993	Epidemiology

A. Positions and Honors.**Positions and Employment**

1978 – 1979 Lecturer, Division of Pharmacology, School of Pharmacy, U. of Wisc., Madison
 1978 – 1980 Project Specialist, Div. of Pharmacology, School of Pharmacy, U. of Wisc., Madison
 1980 – 1983 Project Specialist, Dept of Psychiatry, U. of Wisc., Madison
 1983 – 1995 Staff Research Associate, Dept. of Psychiatry, UCLA
 1994 – 1998 Adj. Asst. Prof., Assistant Researcher, Dept. of Epidemiology, UCLA
 1998 – Present Adj. Assoc. Prof., Assoc. Researcher, Dept. of Epidemiology, UCLA

Other Experience and Professional Memberships

International Society for Pharmacoepidemiology
 Obsessive-Compulsive Foundation

Honors

1972 Graduated with Distinction, Univ. of Wisconsin, Madison
 1986 – 1993 Bertha Unger Career Development Award, UCLA Neuropsychiatric Institute
 1987 Special Performance Award, UCLA Neuropsychiatric Institute
 1990 Administrative and Professional Staff Achievement Award, UCLA School of Medicine
 1995 New Investigator Award, New Clinical Drug Evaluation Unit, NIMH

B. Selected peer-reviewed publications (in chronological order). (Partial list)

1. **Ackerman DL**, Rudy TA. Thermoregulatory characteristics of neurogenic hyperthermia. *Journal of Physiology* 1980;307:59-70.
2. Jefferson JW, Greist JH, **Ackerman DL**. *Lithium Encyclopedia for Clinical Practice*. Washington, DC: American Psychiatric Press, Inc., 1983.
3. **Ackerman DL**, Jefferson JW, Greist JH, Baudhuin MG, Vukovich J. The Lithium Index: An innovative approach to consultation by computer. *Am J Psychiatry* 1984;141:415-417.
4. Jefferson JW, Kaufman P, **Ackerman D**. Tear lithium concentration: A measurement of dubious clinical value. *J Clin Psychiatry* 1984;45:304-305.
5. Greist JH, Jefferson JW, **Ackerman DL**, Baudhuin MG, Erdman HP, Carrol JA. Lithium Information Center: The Lithium Library revisited. *J Clin Psychiatry* 1985;46:327-331.
6. Kaufman PL, Jefferson JW, **Ackerman D**, Baumgartner S. Ocular effects of oral lithium in humans. *Acta Ophthalmology* 1985;63:327-332.

Principal Investigator/Program Director (Last, First, Middle):

7. Jefferson JW, Greist JH, **Ackerman DL**, Carroll J. Lithium Encyclopedia for Clinical Practice (2nd. Edition). Washington, DC: American Psychiatric Press, Inc., 1987.
8. Bystritsky A, **Ackerman DL**, Pasnau RO. Low dose desipramine treatment of cocaine-related panic attacks. *J Nerv and Mental Disease* 1991;179:755-758.
9. **Ackerman DL**. A history of drug testing. In: Coombs RH, West LJ (Eds), *Drug Testing: Issues and Options*. New York: Oxford University Press, 1991, pp 3-21.
10. West LJ, **Ackerman DL**. The drug-testing controversy. *Journal of Drug Issues* 1993;23:579-595.
11. **Ackerman DL**, Greenland S, Bystritsky A, Morgenstern H, Katz RJ. Predictors of treatment response in obsessive compulsive disorder: Multivariate analyses from a multicenter trial of clomipramine. *J Clin Psychopharmacology* 1994;14:247-254.
12. Dotson JW, **Ackerman DL**, West LJ. Ketamine abuse. *Journal of Drug Issues* 1995;25:751-757.
13. Greenland S, **Ackerman DL**. Clomiphene and neural-tube defects: a pooled analysis of controlled epidemiologic studies. *Fertil Steril* 1995;64:936-941.
14. **Ackerman DL**. Drug abuse prevention: The role of drug testing. In: Coombs RH, Ziedonis D (Eds), *Handbook of Drug Abuse Prevention*. Boston: Allyn and Bacon, 1995, pp 473-489.
15. **Ackerman DL**, Greenland S, Bystritsky A, Katz RJ. Relationship between early side effects and therapeutic effects of clomipramine therapy in OCD. *J Clin Psychopharmacology* 1996;16:324-328.
16. **Ackerman DL**, Greenland S, Bystritsky A. A receiver-operator characteristic (ROC) analysis of response to clomipramine therapy. *Psychopharmacology Bulletin* 1996;32:157-165.
17. **Ackerman DL**, Greenland S, Bystritsky A, Small GW. Characteristics of fluoxetine vs. placebo responders in a randomized trial of geriatric depression. *Psychopharmacology Bulletin* 1997;33:707-714.
18. **Ackerman DL**, Greenland S, Bystritsky A. Clinical characteristics of responders to fluoxetine treatment of OCD. *Journal of Clinical Psychopharmacology* 1998;18:185-192.
19. **Ackerman DL**, Greenland S, Bystritsky A. Side effects as predictors of drug response in OCD. *Journal of Clinical Psychopharmacology* 1999;19:459-465.
20. **Ackerman DL**, Greenland S, Bystritsky A, Small GW. Side effects and time course of response in a placebo-controlled trial of fluoxetine in geriatric depression. *Journal of Clinical Psychopharmacology* 2000;20:658-65.
21. **Ackerman DL**, Greenland S. Multivariate meta-analysis of controlled drug studies for OCD. *Journal of Clinical Psychopharmacology* 2002;22:309-17.
22. **Ackerman DL**, Unutzer J, Greenland S, Gitlin M. Inpatient treatment of depression and associated hospital charges. *Pharmacoepidemiology and Drug Safety* 2002;11:219-27.
23. **Ackerman DL**, Cameron ME. Energy healing for anxiety and stress-reduction. *Primary Psychiatry* 2002;9:53-58.

C. Research Support

Ongoing Research Support

K01 MH01513 Ackerman (PI)

8/01/98-7/31/04

NIMH

OCD Treatment Outcomes: Beyond Phase 3 Drug Trials

The major goals of this project are to gain additional training in pharmacoepidemiology, psychological and neurological assessment, neuroimaging, and statistical analysis; and to conduct an observational study of treatment response among clinic patient with obsessive-compulsive disorder.

Role: PI

Ackerman (PI)

11/01/00-10/31/03

Alzheimer's Association

Assessment Scale for End-of-Life Care for End-Stage Dementia.

The goal of this project is to collect and analyze data retrospectively from nursing home and clinic patients with severe, end-stage Alzheimer's disease and other forms of dementia, to identify clinical factors associated risk of death within one-year, and to develop an assessment scale to estimate the short-term survival probability of an individual patient.

Role: PI

Ackerman (PI)

12/01/00-11/30/03

Rockefeller Brothers Fund

Principal Investigator/Program Director (Last, First, Middle):

A Clinical Assessment Scale To Predict Survival In End-Stage Dementia.

The goal of this project is to collect and analyze data retrospectively from hospice and nursing home patients with severe, end-stage Alzheimer's disease and other forms of dementia, to identify clinical factors associated risk of death within one-year, and to develop an assessment scale to estimate the short-term survival probability of an individual patient.

Role: PI

Completed Research Support

R03 MH53873 Ackerman (PI) 1995-1996

PHS/NIMH

Predictors of Response to SSRIs in OCD, (I).

This project was a secondary analysis of data from Phase III clinical trials of clomipramine and of fluoxetine for obsessive-compulsive disorder to identify predictors of response.

Role: PI

Ackerman (PI) 1995-1997

The Kenneth T. and Eileen L. Norris Foundation.

Predictors of Response to Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder, (II).

This project was an extension of the analysis of data from multisite clinical trials of clomipramine and fluoxetine for obsessive-compulsive disorder to compare response profiles.

Role: PI

R03 MH53935 Ackerman (PI) 1996-1998

PHS/ NIMH

Fluoxetine in Geriatric Depression: Response Prediction.

This project was a secondary analysis of data from a multisite clinical trial of fluoxetine for geriatric depression to identify predictors of response to active drug and to placebo.

Role: PI

R03 HS90213 Ackerman (PI) 1997-1998

PHS/AHRQ

Outcomes and Cost of Inpatient Antidepressant Drugs.

This project represented an observational retrospective study of inpatient treatment of depression, the utilization of antidepressant medications, and the hospital charges associated with different drug regimens.

Role: PI